SUPN
HEALTHCARESupernus Pharmaceuticals Inc
$51.45+2.26 (+4.59%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving SUPN Today?
No stock-specific AI insight has been generated for SUPN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$30.83$59.68
$51.45
Fundamentals
Market Cap$3.0B
P/E Ratio—
EPS$-0.51
Dividend Yield—
Dividend / Share—
ROE-0.0%
Profit Margin-0.0%
Debt / Equity—
Trading
Volume1.9M
Avg Volume (10D)—
Shares Outstanding58.0M
SUPN News
20 articles- Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care ConferenceYahoo Finance·May 6, 2026
- Does Q1 2026 Earnings Beat Reshape the Bull Case for Supernus Pharmaceuticals (SUPN)?Yahoo Finance·May 6, 2026
- Supernus Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- Supernus Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMoby·May 6, 2026
- Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesYahoo Finance·May 5, 2026
- Supernus (SUPN) Q1 2026 Earnings TranscriptMotley Fool·May 5, 2026
- Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue EstimatesYahoo Finance·May 5, 2026
- Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 CY2026 Sales Beat EstimatesYahoo Finance·May 5, 2026
- Supernus Announces First Quarter 2026 Financial ResultsYahoo Finance·May 5, 2026
- Supernus Pharmaceuticals Earnings: What To Look For From SUPNYahoo Finance·May 4, 2026
- Branded Pharmaceuticals Stocks Q4 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)Yahoo Finance·Apr 27, 2026
- Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?Yahoo Finance·Apr 24, 2026
- Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026Yahoo Finance·Apr 22, 2026
- Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To KnowYahoo Finance·Apr 18, 2026
- 3 Unprofitable Stocks We Think Twice AboutYahoo Finance·Apr 14, 2026
- 1 Cash-Producing Stock to Consider Right Now and 2 Facing HeadwindsYahoo Finance·Apr 13, 2026
- Supernus Pharma Insider Sells $5.4 Million as Stock Surges 53% in a YearMotley Fool·Mar 27, 2026
- 3 Reasons SUPN is Risky and 1 Stock to Buy InsteadYahoo Finance·Mar 12, 2026
- Is It Too Late To Consider Supernus Pharmaceuticals (SUPN) After A 74% One Year Rally?Yahoo Finance·Mar 3, 2026
- Supernus Pharmaceuticals, Inc. Q4 2025 Earnings Call SummaryMoby·Feb 25, 2026
All 20 articles loaded
Price Data
Open$50.67
Previous Close$49.19
Day High$51.50
Day Low$46.87
52 Week High$59.68
52 Week Low$30.83
52-Week Range
$30.83$59.68
$51.45
Fundamentals
Market Cap$3.0B
P/E Ratio—
EPS$-0.51
Dividend Yield—
Dividend / Share—
ROE-0.0%
Profit Margin-0.0%
Debt / Equity—
Trading
Volume1.9M
Avg Volume (10D)—
Shares Outstanding58.0M
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases of the central nervous system in the United States. The company is headquartered in Rockville, Maryland.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—